Lytix Biopharma AS

Regulatory Filings • Dec 11, 2025

LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

Oslo, Norway, 11 December 2025: Primary insider Øystein Rekdal, Chief Executive Officer of Lytix Biopharma AS, has today acquired 10,000 shares in Lytix Biopharma AS at a price of NOK 9.9984 per share. Following the transaction, Øystein Rekdal holds 176,179 shares in Lytix Biopharma AS.

Disclosure regulation:

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

Visit www.lytixbiopharma.com.